These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34580638)

  • 1. Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.
    Cai TT; Li HQ; Jiang LL; Wang HY; Luo MH; Su XF; Ma JH
    Biomed Res Int; 2021; 2021():3361309. PubMed ID: 34580638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like Peptide-1 Receptor Agonists and Diabetic Osteopathy: Another Positive Effect of Incretines? A 12 Months Longitudinal Study.
    Al Refaie A; Baldassini L; Mondillo C; Ceccarelli E; Tarquini R; Gennari L; Gonnelli S; Caffarelli C
    Calcif Tissue Int; 2024 Aug; 115(2):160-168. PubMed ID: 38864922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.
    Boye KS; Mody R; Wu J; Lage MJ; Botros FT; Woodward B
    Clin Ther; 2018 Aug; 40(8):1396-1407. PubMed ID: 30093131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
    Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
    Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus.
    Akyay OZ; Canturk Z; Selek A; Cetinarslan B; Tarkun İ; Cakmak Y; Baydemir C
    Medicine (Baltimore); 2023 Sep; 102(39):e35394. PubMed ID: 37773814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
    Chun JH; Butts A
    JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
    Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
    Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
    Tuttle KR; McKinney TD; Davidson JA; Anglin G; Harper KD; Botros FT
    Diabetes Obes Metab; 2017 Mar; 19(3):436-441. PubMed ID: 27766728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
    Triplitt C; Solis-Herrera C
    Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.
    Fuechtenbusch M; Aberle J; Heitmann E; Nicolay C; Jung H
    Diabetes Obes Metab; 2019 Jun; 21(6):1340-1348. PubMed ID: 30737891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
    Chun JH; Butts A
    JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.
    Ishii H; Madin-Warburton M; Strizek A; Thornton-Jones L; Suzuki S
    J Med Econ; 2018 May; 21(5):488-496. PubMed ID: 29357718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis.
    Xu J; Yao D; Xia J
    J Clin Pharm Ther; 2021 Oct; 46(5):1245-1253. PubMed ID: 33675117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
    Edelman SV
    J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Patel D
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
    Mody R; Yu M; Nepal B; Konig M; Grabner M
    Diabetes Obes Metab; 2021 Jan; 23(1):106-115. PubMed ID: 32945083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Plethora of GLP-1 Agonists: Decisions About What to Use and When.
    Samson SL; Garber AJ
    Curr Diab Rep; 2016 Dec; 16(12):120. PubMed ID: 27766579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.